ABBV-101 is positioned as a novel therapeutic option for patients with relapsed or refractory B-cell malignancies, particularly Non-Hodgkin's lymphoma (NHL). The trial's design includes both a dose escalation and expansion phase, indicating AbbVie's commitment to exploring ABBV-101's potential in various treatment lines, including combinations with established therapies like venetoclax. The market for NHL treatments is competitive, with several existing therapies, including BTK inhibitors and CAR-T therapies. However, ABBV-101's unique mechanism as a BTK degrader may provide a differentiated profile, potentially addressing unmet needs in patients who have exhausted current treatment options. The trial's global scope and inclusion of multiple NHL subtypes suggest a strategic approach to capture a broad patient population, enhancing market potential. Diligence should focus on the safety profile and efficacy data as they emerge, particularly in comparison to existing therapies.